U.S. markets open in 1 hour 33 minutes
  • S&P Futures

    4,575.00
    +17.00 (+0.37%)
     
  • Dow Futures

    35,720.00
    +100.00 (+0.28%)
     
  • Nasdaq Futures

    15,586.75
    +91.00 (+0.59%)
     
  • Russell 2000 Futures

    2,317.80
    +7.50 (+0.32%)
     
  • Crude Oil

    83.97
    +0.21 (+0.25%)
     
  • Gold

    1,804.50
    -2.30 (-0.13%)
     
  • Silver

    24.44
    -0.15 (-0.62%)
     
  • EUR/USD

    1.1621
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    14.96
    -0.47 (-3.05%)
     
  • GBP/USD

    1.3814
    +0.0045 (+0.33%)
     
  • USD/JPY

    113.9490
    +0.2500 (+0.22%)
     
  • BTC-USD

    62,799.42
    -52.97 (-0.08%)
     
  • CMC Crypto 200

    1,508.65
    +1,265.97 (+521.66%)
     
  • FTSE 100

    7,266.34
    +43.52 (+0.60%)
     
  • Nikkei 225

    29,106.01
    +505.60 (+1.77%)
     

Nemaura Medical Announces Progress on Listing of sugarBEAT® For Reimbursement in Germany

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Loughborough, England, May 06, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced progress with the German regulatory authority (GBA) to achieve reimbursement for its sugarBEAT® device.

After initial review, the GBA has determined that sugarBEAT does not require GBA review and will go directly to the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) for a listing on the durable medical catalog. The Company is now completing the application for this listing, which is expected to be faster than where a GBA review is required.

“The availability of SugarBEAT® in Germany would be an important milestone for Nemaura and we are actively collaborating with the appropriate agencies to ensure timely availability there,” said Nemaura CEO Dr. Faz Chowdhury. “In the meantime, we are actively negotiating to identify the right partner to market and distribute the product and our program in this very important market. We will continue to provide updates as appropriate on our progress.”

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.

The Company believes that it sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com